glp 1 mechanism of action diagram Glucagon-like peptide-1 receptor: mechanisms and advances in therapy The Physiology of Glucagon-like Peptide
Description
After stopping the medication, my depression began to lift within two weeks, and my vision returned to normal
308 , E414E425 (2015)
Conclusion Clinical trial data from large, controlled studies demonstrate the efficacy and safety of GLP-1 agonists in terms of A1C reduction, beneficial effects on body weight, and a low risk for hypoglycemic events when used as monotherapy
It is a recognised cause of post-meal sneezing and is unrelated to bariatric surgery, though it may be more noticeable after gastric sleeve surgery
